|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM214616843 |
| 003 |
DE-627 |
| 005 |
20240322233418.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2012 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1021/la2042185
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1340.xml
|
| 035 |
|
|
|a (DE-627)NLM214616843
|
| 035 |
|
|
|a (NLM)22251479
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Xie, Hui
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a One-step fabrication of polymeric Janus nanoparticles for drug delivery
|
| 264 |
|
1 |
|c 2012
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 29.06.2012
|
| 500 |
|
|
|a Date Revised 22.03.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a With its unique structure of two compartments, Janus particles can be used for many applications for which monomorphic particles are inadequate, including to be used as a drug delivery system to deliver multiple payloads with widely different solubility. Here we report on a fluidic nanoprecipitation system (FNPS), capable of fabricating biocompatible Janus polymeric nanoparticles comprised of the FDA-approved polymer poly(lactic-co-glycolic acid) (PLGA). The FNPS contains dual inlets, one for each half of the particle, that insert into the precipitation stream. The system provides a one-step approach for production of Janus polymeric particles with submicrometer diameters and is likely amenable to substantial scale-up. To the best of our knowledge, this is the first demonstration of biocompatible Janus nanoparticles that encapsulate a hydrophobic drug (paclitaxel) on one side and a hydrophilic drug (doxorubicin hydrochloride) on the other
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
7 |
|a Polymers
|2 NLM
|
| 650 |
|
7 |
|a Polylactic Acid-Polyglycolic Acid Copolymer
|2 NLM
|
| 650 |
|
7 |
|a 1SIA8062RS
|2 NLM
|
| 650 |
|
7 |
|a Polyglycolic Acid
|2 NLM
|
| 650 |
|
7 |
|a 26009-03-0
|2 NLM
|
| 650 |
|
7 |
|a Lactic Acid
|2 NLM
|
| 650 |
|
7 |
|a 33X04XA5AT
|2 NLM
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Paclitaxel
|2 NLM
|
| 650 |
|
7 |
|a P88XT4IS4D
|2 NLM
|
| 700 |
1 |
|
|a She, Zhi-Gang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Si
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sharma, Gaurav
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Smith, Jeffrey W
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Langmuir : the ACS journal of surfaces and colloids
|d 1992
|g 28(2012), 9 vom: 06. März, Seite 4459-63
|w (DE-627)NLM098181009
|x 1520-5827
|7 nnns
|
| 773 |
1 |
8 |
|g volume:28
|g year:2012
|g number:9
|g day:06
|g month:03
|g pages:4459-63
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1021/la2042185
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_721
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 28
|j 2012
|e 9
|b 06
|c 03
|h 4459-63
|